Comprehensive Assessment of Cancer Theranostic Response

Recruiting now · Not applicable

Conditions studied: Prostate Cancer

In brief

The intent of this study is to evaluate actionable outputs from TRAQinform Theranostics in a prospective, multi-center, non-interventional clinical study. The primary objective is to investigate intent-to-change treatment decisions after the addition of TRAQinform Theranostics. The exploratory objective is to investigate if treatment efficacy and treatment-related toxicity could be detected by TRAQinform Theranostics following PSMA PET/CT at week 12.

Key facts

Study ID

NCT06815354

Run by

AIQ Solutions

People needed

32

Starts

2024-12-02

Expected to finish

2026-05-29

Last updated by the study team

2025-09-09

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older and willing and able to provide informed consent.
• Diagnosis of metastatic prostate cancer.
• Planned to start 177Lu-PSMA (Pluvicto).
• Ability to tolerate two 68Ga-PSMA or 18F-DCFPyL PET/CT imaging procedures. One at baseline and at 12 weeks of 177Lu-PSMA (Pluvicto) treatment.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 at screening.

You may not qualify if…

• Any concurrent disease, infection, or comorbid condition that interferes with the ability of the patient to participate in the trial.

Where it is running

• Weill Medical College of Cornell — New York, New York, United States (enrolling)
• M.D. Anderson Cancer Center — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.